All You Need To Know About The German Marijuana Market: Changes, Size And Leading Players
Portfolio Pulse from Nicolás Jose Rodriguez
Pablo Zuanic forecasts Germany's medical cannabis market to grow to €1.7 billion by 2025, driven by legislative changes and increased accessibility. Canadian companies Aurora (ACB) and Tilray (TLRY), along with Curaleaf (CURLF) through its German subsidiary Four20 Pharma, are well-positioned to benefit from this growth. The introduction of cannabis social clubs and easier prescription processes are key growth drivers.
February 28, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurora is expected to benefit significantly from Germany's growing medical cannabis market, leading the cash market segment.
Aurora's strong export ties to Germany and its leading position in the cash market segment position it to capitalize on the market growth driven by legislative changes and increased accessibility.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Curaleaf, through its German subsidiary Four20 Pharma, is poised to leverage its connections and benefit from Germany's medical cannabis market growth.
Curaleaf's ownership of Four20 Pharma, a German importer sourcing from Canadian producers, positions it to benefit from the market growth facilitated by legislative changes and increased accessibility.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Tilray is well-positioned to benefit from Germany's medical cannabis market expansion, especially in the reimbursed sector.
Tilray's dominance in the reimbursed sector and its strong export ties to Germany make it a key beneficiary of the market's growth, driven by easier access and legislative changes.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80